|
Neuroendocrine Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SATB2 is frequently and strongly expressed by lower GI tract NETs; we have adopted it as our rectal NET marker.
|
31233624 |
2020 |
|
Neuroendocrine Tumors
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence.
|
31097087 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Appendiceal carcinoid (neuroendocrine tumor or NET) is a rare neuroendocrine neoplasm often found incidentally following appendectomy for appendicitis.
|
31555859 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent updates separate pancreatic neuroendocrine tumors into 2 broad categories: well-differentiated pancreatic neuroendocrine tumors (panNET) and poorly differentiated pancreatic neuroendocrine carcinoma (panNEC), and incorporates a new subcategory of "well-differentiated high-grade NET (G3)" to the well-differentiated NET category.
|
29912000 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The category of grade 3 neuroendocrine tumor (NET G3) was newly introduced in the 2017 World Health Organization (WHO 2017) classification of neuroendocrine neoplasms of the pancreas.
|
31511024 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
This work presents a first preclinical assessment of this state-of-the-art OV, using a panel of human neuroendocrine tumor/neuroendocrine carcinoma (NET/NEC) cell lines.
|
31280274 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Fifty-seven patients with G1, G2, and low G3 NETs with liver metastases were investigated (pancreatic NET (pNET), 24; small bowel, 16; unknown origin (UKO), 9; rectal, 3; lung, 3; and gastric, 2).
|
29383678 |
2018 |
|
Neuroendocrine Tumors
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Grade 3 neuroendocrine tumor (NET G3) is a rare new entity that has recently been introduced in the classification of neuroendocrine neoplasms of the pancreas.
|
29675587 |
2018 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
TeleNEN as a telemedicine model for neuroendocrine neoplasm management in case of Meckel's diverticulum NET.
|
29952421 |
2018 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
The WHO 2017 classification introduces the novel well-differentiated neuroendocrine tumor of high grade (NET G3).
|
30098710 |
2018 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
We identified 414 patients with GI-NENs, 250 cases were diagnosed as neuroendocrine tumor G1 (NET G1), 25 as neuroendocrine tumor G2 (NET G2), 53 as neuroendocrine tumor G3 (NET G3), 55 as neuroendocrine carcinoma G3 (NEC G3), and 31 as mixed adenoneuroendocrine carcinoma (MANEC); the overall survival (OS) rate at three years were 94.9%, 91.7%, 74.3%, 62.7% and 38.1%, respectively.
|
28856815 |
2018 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data supports the use of specific NET biomarkers based on the site of the primary NET and the presence of hereditary syndrome-associated NET.
|
28289088 |
2017 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
ACTH = adrenocorticotropic hormone CT = computed tomography DOTATATE = <sup>68</sup>Ga-DOTA-Tyr<sup>3</sup>-octreotate ECS = ectopic Cushing syndrome FDG = fluorodeoxyglucose MTC = medullary thyroid cancer NET = neuroendocrine tumor PET = positron emission tomography.
|
28614007 |
2017 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
At histological examination, 81 patients had a gastric neuroendocrine neoplasia (42 patients had a NET G1 and 33 a NET G2).The median Ki67 index was 2.0 %.
|
27592118 |
2017 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.
|
29091800 |
2017 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies indicated that PanNEN-G3 includes well-differentiated neuroendocrine tumor with G3 (NET-G3).
|
28455360 |
2017 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
ACTH = adrenocorticotropic hormone; BIPSS = bilateral inferior petrosal sinus sampling; CBG = corticosteroid-binding globulin; CD = Cushing disease; CRH = corticotropin-releasing hormone; CS = Cushing syndrome; Dex = dexamethasone; DST = dexamethasone suppression test; EAS = ectopic ACTH syndrome; FDA = U.S. Food & Drug Administration; HDDST = high-dose DST; IPS/P = inferior petrosal sinus to peripheral; MRI = magnetic resonance imaging; NET = neuroendocrine tumor; PET = positron emission tomography; UFC = urinary free cortisol.
|
28614036 |
2017 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
GI = gastrointestinal; ICD-9-CM = International Classification of Diseases, 9th Revision, Clinical Modification; NET = neuroendocrine tumor; PMPY = per million person-years; SEER = Surveillance, Epidemiology, and End Results.
|
28704096 |
2017 |
|
Neuroendocrine Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DMSG = DutchMEN1 Study Group; D-NET = duodenal neuroendocrine tumor; DP-NET = duodenopancreatic neuroendocrine tumor; HPF = high-power field; Ki67 LI = Ki67 labeling index; MEN1 = multiple endocrine neoplasia type 1; NET = neuroendocrine tumor; OS = overall survival; P-NET = pancreatic neuroendocrine tumor; PPI = proton pump inhibitor; ULN = upper limit of normal; WHO = World Health Organization.
|
28225311 |
2017 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Neuroendocrine tumors of the small intestine (SI-NETs) exhibit an increasing incidence and high mortality rate.
|
27222126 |
2017 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinicopathologic correlation was made among poorly differentiated neuroendocrine carcinomas (NECs/poorly differentiated histology and Ki-67 >20%) and pancreatic neuroendocrine tumours (PanNETs/Ki67 ⩽20%) and non-pancreatic neuroendocrine tumours (NP-NETs/Ki67 ⩽20%).
|
27482646 |
2016 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
In order to evaluate biomarker precision and identify if combinatorial blood molecular markers and imaging could provide added diagnostic value, we assessed the concordance between (68)Ga-somatostatin analog (SSA) positron emission tomography (PET), circulating NET gene transcripts (NETest), chromogranin A (CgA), and Ki-67 in NETs.
|
25947577 |
2015 |
|
Neuroendocrine Tumors
|
0.100 |
GeneticVariation
|
group |
BEFREE |
IL-2 -330 T/G SNP and serum values-potential new tumor markers in neuroendocrine tumors of the gastrointestinal tract and pancreas (GEP-NETs).
|
20049409 |
2010 |